TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31499518

Group type: EXPERIMENTAL
Intervention: PrEP initiation
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: PrEP first discontinuation
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: PrEP final discontinuation
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: HIV incidence
Number of subjects: 440
Study: 31500448

Group type: EXPERIMENTAL
Intervention: TAPSE/PASP
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: TAPSE/PASP cutoff of 0.31 mm/mm Hg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: TAPSE/PASP, fractional area change/mean pulmonary artery pressure, RV area change/end-systolic area, stroke volume/end-systolic area
Number of subjects: 52

Group type: COMPARATOR
Intervention: TAPSE/pulmonary artery acceleration time
Number of subjects: 52
Study: 31500552

Group type: EXPERIMENTAL
Intervention: Hypocapnia via hyperventilation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study: 31500586

Group type: EXPERIMENTAL
Intervention: Cetuximab in combination with irinotecan and fluorouracil
Number of subjects: 34
Study: 31500595

Group type: EXPERIMENTAL
Intervention: Olaparib in combination with radical (chemo-)radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olaparib in combination with radical (chemo-)radiotherapy and concurrent low dose cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 0
Study: 31500607

Group type: EXPERIMENTAL
Intervention: Chronic Bronchitis (CB)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Emphysema (EM)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Presence of symptoms during the 24-h day (CB and EM)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Night-time symptoms (CB vs EM)
Number of subjects: 606
Study: 31501119

Group type: EXPERIMENTAL
Intervention: Retired professional footballers
Number of subjects: 572

Group type: COMPARATOR
Intervention: General population controls
Number of subjects: 572
Study: 31501123

Group type: EXPERIMENTAL
Intervention: Robotic guidance (RG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation (NV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Freehand (FH) surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analgesic medication use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Work status
Number of subjects: 0
Study: 31501122

Group type: EXPERIMENTAL
Intervention: Tolerogenic dendritic cells (tolDC) administered via intradermal injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolerogenic dendritic cells (tolDC) administered via intranodal injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolerogenic dendritic cells (tolDC)
Number of subjects: 0
Study: 31501130

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome (PRO) measure to assess financial toxicity (FT) in cancer patients
Number of subjects: 0
Study: 31501132

Group type: EXPERIMENTAL
Intervention: Daily screening for readiness to discontinue MV
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Modes of MV used before initial discontinuation attempts
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Weaning and spontaneous breathing trial (SBT) protocols
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: SBT techniques
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Sedation and mobilisation practices to facilitate weaning and discontinuation
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: SBT outcome (failure vs success)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Timing of SBT (early vs later in ICU stay)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Different SBT techniques and humidification strategies
Number of subjects: 1500
Study: 31501599

Group type: EXPERIMENTAL
Intervention: Gene-corrected hematopoietic stem cells
Number of subjects: 0
Study: 31501600

Group type: EXPERIMENTAL
Intervention: Sensory feedback restoration in leg amputees
Number of subjects: 0
Study: 31501975

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type A (BoNT-A) treatment
Number of subjects: 100
Study: 31501989

Group type: EXPERIMENTAL
Intervention: Virtual planning using customized surgical devices (VP3D)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional surgery (CS)
Number of subjects: 30
Study: 31502117

Group type: EXPERIMENTAL
Intervention: Aprutumab ixadotin (0.1-1.3 mg/kg, administered intravenously on day 1 of every 21-day cycle)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aprutumab ixadotin
Number of subjects: 20
Study: 31502238

Group type: EXPERIMENTAL
Intervention: Self-management support provided by trained respiratory educators
Number of subjects: 54
Study: 31502330

Group type: EXPERIMENTAL
Intervention: Epicardial adipose tissue (EAT) assessment using multislice computed tomography before AF ablation
Number of subjects: 3464

Group type: EXPERIMENTAL
Intervention: Prior thromboembolism (TE) history
Number of subjects: 3464

Group type: EXPERIMENTAL
Intervention: Lower creatinine clearance (CCr)
Number of subjects: 3464
Study: 31502400

Group type: EXPERIMENTAL
Intervention: Cediranib at the pediatric maximum tolerated dose of 12 mg/m²
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cediranib
Number of subjects: 7
Study: 31502421

Group type: EXPERIMENTAL
Intervention: Mepolizumab SC 40 mg (bodyweight <40 kg) or 100 mg (≥40 kg) every 4 weeks for 12 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mepolizumab SC 40 mg or 100 mg
Number of subjects: 36
Study: 31502485

Group type: EXPERIMENTAL
Intervention: Low NAb titers (<1:5)
Number of subjects: 0
Study: 31502936

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-statin users)
Number of subjects: 0
Study: 31503017

Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy (cases 1-25)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy (cases 26-65)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy (cases 66-88)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy (cases 89-125)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy
Number of subjects: 502
Study: 31503159

Group type: EXPERIMENTAL
Intervention: Xeroderma pigmentosum females
Number of subjects: 60
Study: 31504095

Group type: EXPERIMENTAL
Intervention: Norovirus infection
Number of subjects: 52
Study: 31504107

Group type: EXPERIMENTAL
Intervention: WHRadjBMI GRS
Number of subjects: 9895

Group type: EXPERIMENTAL
Intervention: Genetically instrumented 1-SD increase in WHRadjBMI
Number of subjects: 9895
Study: 31504335

Group type: EXPERIMENTAL
Intervention: CMV viremia (detected CMV DNA, median plasma viral load 498 IU/mL, IQR 259-2390)
Number of subjects: 111

Group type: COMPARATOR
Intervention: No CMV viremia (not detected CMV DNA)
Number of subjects: 111
Study: 31504342

Group type: EXPERIMENTAL
Intervention: Depot Medroxyprogesterone Acetate (DMPA) 150 mg intramuscular injection
Number of subjects: 42

Group type: COMPARATOR
Intervention: Historical controls (not specified)
Number of subjects: 42
Study: 31504405

Group type: EXPERIMENTAL
Intervention: Presence of minimum lumen area (MLA) <3.5 mm2
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Presence of fibrous cap thickness (FCT) <75 µm
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Presence of lipid arc circumferential extension >180°
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Presence of OCT-defined macrophages
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Simultaneous presence of the four OCT criteria in the same plaque
Number of subjects: 1003
Study: 31504674

Group type: EXPERIMENTAL
Intervention: BCG vaccination (presence of a scar or vaccination history)
Number of subjects: 3453

Group type: COMPARATOR
Intervention: Non-vaccinated participants
Number of subjects: 3453
Study: 31504882

Group type: EXPERIMENTAL
Intervention: Nicotine-containing e-cigarette for 7 days followed by 6 days of abstinence
Number of subjects: 30
Study: 31504985

Group type: EXPERIMENTAL
Intervention: Dual-energy CT (DECT)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Clinical+serum urate subset
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Clinical-only subset
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Clinical subset
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Clinical+serum urate subset with DECT
Number of subjects: 89
Study: 31505615

Group type: EXPERIMENTAL
Intervention: New-onset left bundle branch block (LBBB) at discharge
Number of subjects: 1179
Study: 31506079

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental assessment at 12 months using the ages and stages questionnaire (ASQ)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental assessment at 24 months using the Bayley-III test
Number of subjects: 150
Study: 31506080

Group type: EXPERIMENTAL
Intervention: Novel FSHD functional composite COA made up of 18 evaluator-administered motor tasks in the domains of shoulder/arm, hand, core/abdominal, leg, and balance function
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Electrical impedance myography as a novel muscle quality biomarker
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Domain 1 of the Motor Function Measure
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Reachable workspace
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Orofacial strength using the Iowa Oral Performance Instrument
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Lean muscle mass using dual-energy X-ray absorptiometry (DEXA)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Strength as measured by quantitative myometry and manual muscle testing
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: FSHD Health Index and other patient-reported outcomes
Number of subjects: 220
Study: 31506084

Group type: EXPERIMENTAL
Intervention: Wine consumption
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Total alcohol consumption
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Non-smoking status
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Beer and spirit consumption
Number of subjects: 720
Study: 31506182

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation
Number of subjects: 26
Study: 31506337

Group type: EXPERIMENTAL
Intervention: Oxygen delivery systems
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High oxygen flows
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Normal tidal volume breathing
Number of subjects: 10
Study: 31506385

Group type: EXPERIMENTAL
Intervention: Dabrafenib (specific dosage and duration not provided)
Number of subjects: 27
Study: 31506387

Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (Rova-T) 0.3 mg/kg once every 6 weeks for two cycles
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (Rova-T)
Number of subjects: 339
Study: 31507322

Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other Atypical Antipsychotics (AAPs)
Number of subjects: 0
Study: 31507641

Group type: EXPERIMENTAL
Intervention: Mepolizumab (add-on maintenance therapy)
Number of subjects: 34
Study: 31508232

Group type: EXPERIMENTAL
Intervention: Oral health education intervention (three educational sessions over a six-week period)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Regular dental visits
Number of subjects: 46
Study: 31508483

Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 1604

Group type: EXPERIMENTAL
Intervention: Renal dysfunction (RD)
Number of subjects: 1604

Group type: EXPERIMENTAL
Intervention: Anemia in patients with NYHA class III-IV
Number of subjects: 1604
Study: 31508518

Group type: EXPERIMENTAL
Intervention: Ibrutinib (50 mg/kg p.o daily for three weeks)
Number of subjects: 0
Study: 31509537

Group type: EXPERIMENTAL
Intervention: ADRe monitoring
Number of subjects: 30
Study: 31509667

Group type: EXPERIMENTAL
Intervention: CRISPR-Edited Stem Cells
Number of subjects: 1
Study: 31509815

Group type: EXPERIMENTAL
Intervention: FAST-LIFE arrays (longitudinal intrafascicular arrays and fascicular cuff electrodes) implanted in sensory fascicles
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: FAST-LIFE arrays (longitudinal intrafascicular arrays and fascicular cuff electrodes) implanted in motor fascicles
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: FAST-LIFE arrays (longitudinal intrafascicular arrays and fascicular cuff electrodes)
Number of subjects: 4
Study: 31510768

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 8380

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8380

Group type: EXPERIMENTAL
Intervention: Congestion reduction
Number of subjects: 8380

Group type: EXPERIMENTAL
Intervention: Physical examination signs of congestion
Number of subjects: 8380
Study: 31510769

Group type: EXPERIMENTAL
Intervention: Gastrointestinal bleeding
Number of subjects: 27395

Group type: EXPERIMENTAL
Intervention: Genitourinary bleeding
Number of subjects: 27395

Group type: EXPERIMENTAL
Intervention: Urinary bleeding
Number of subjects: 27395

Group type: EXPERIMENTAL
Intervention: Nongastrointestinal, nongenitourinary bleeding
Number of subjects: 27395
Study: 31510865

Group type: EXPERIMENTAL
Intervention: Novel sequencing technology using molecular inversion probes for cell-free DNA screening
Number of subjects: 1414
Study: 31510897

Group type: EXPERIMENTAL
Intervention: Cancer-stroke group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Stroke-only group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cancer-only group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vascular risk factors group
Number of subjects: 10
Study: 31511239

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 58
Study: 31511876

Group type: EXPERIMENTAL
Intervention: T1DM-Unaware
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: T1DM-Aware
Number of subjects: 39

Group type: COMPARATOR
Intervention: HC
Number of subjects: 39
Study: 31511942

Group type: EXPERIMENTAL
Intervention: Electrical Impedance Spectroscopy (EIS)
Number of subjects: 56
Study: 31512728

Group type: EXPERIMENTAL
Intervention: iscalimab (10 mg/kg intravenously over 12 weeks)
Number of subjects: 15
Study: 31513018

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (CIT) with oregovomab (anti-CA-125), gemcitabine/leucovorin/fluorouracil for 3 cycles, followed by nelfinavir (1250 mg bid for 5 weeks) and SBRT (40 Gy/5 fractions) during the third week of nelfinavir.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oregovomab (2 mg) administered for 7 total doses (3 pre-SBRT, 1 between SBRT and resection, and 3 postoperatively)
Number of subjects: 11
Study: 31513090

Group type: EXPERIMENTAL
Intervention: Self-reported physical fitness (PF) assessed with the International Fitness Scale (IFIS)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF), speed-agility, and flexibility
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Muscle strength (MS)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: CRF, MS, and speed-agility
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Flexibility
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Overall PF and all its components
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Overall PF and MS
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Overall PF
Number of subjects: 191
Study: 31513265

Group type: EXPERIMENTAL
Intervention: High-fat (64%) high-energy (+47%) diet for 7 days
Number of subjects: 15
Study: 31513270

Group type: EXPERIMENTAL
Intervention: C-terminal pro-endothelin-1 (CT-proET-1) levels
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Mid-regional pro-adrenomedullin (MR-proADM) levels
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Right ventricular (RV) reserve limitation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Baseline CT-proET-1 and MR-proADM levels
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (free of HF)
Number of subjects: 38
Study: 31513353

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 44
Study: 31514508

Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA) treatment, specific intervention details not available
Number of subjects: 0
Study: 31514524

Group type: EXPERIMENTAL
Intervention: ACT <150 s
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: ACT between 150 and 249 s
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: ACT >250 s
Number of subjects: 837
Study: 31514751

Group type: EXPERIMENTAL
Intervention: 2013 American Thoracic Society CPAP-tracking system algorithm
Number of subjects: 650
Study: 31515130

Group type: EXPERIMENTAL
Intervention: Use of Tacrolimus, use of anti-thymocyte globulins (ATG), higher B cell count, lower recent thymic emigrants (RTE) %
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: B cell count
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Lower RTE%
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Tacrolimus sparing and B cell depletion
Number of subjects: 818
Study: 31515430

Group type: EXPERIMENTAL
Intervention: Simplified CAMI-NSTEMI (SCAMI-NSTEMI) score
Number of subjects: 5775

Group type: EXPERIMENTAL
Intervention: SCAMI-NSTEMI score
Number of subjects: 5775
Study: 31515828

Group type: EXPERIMENTAL
Intervention: GHX02 at 0, 1250, 2500, and 5000 mg/kg/day for 28 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: In vitro tests for genotoxicity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Other genetic toxicity studies
Number of subjects: 20
Study: 31516602

Group type: EXPERIMENTAL
Intervention: gBRCAm OvCa
Number of subjects: 0

Group type: COMPARATOR
Intervention: BRCA wild-type (BRCAwt) disease
Number of subjects: 0
Study: 31516726

Group type: EXPERIMENTAL
Intervention: Interactive Nutrition Comics
Number of subjects: 89

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 89
Study: 31516729

Group type: EXPERIMENTAL
Intervention: Motivational text messages
Number of subjects: 38

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 38
Study: 31516727

Group type: EXPERIMENTAL
Intervention: Eccentric exercise plus acupuncture
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Eccentric exercise plus manual therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Eccentric exercise alone
Number of subjects: 36
Study: 31516734

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg/day for 4 weeks
Number of subjects: 13
Study: 31517177

Group type: EXPERIMENTAL
Intervention: Matched tumor and germline DNA NGS of a targeted panel of 201 genes
Number of subjects: 1000
Study: 31517263

Group type: EXPERIMENTAL
Intervention: Adaptive Servo-Ventilation (ASV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ASV
Number of subjects: 40

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 40
Study: 31518248

Group type: EXPERIMENTAL
Intervention: Virtual Cognitive Health (VC Health) program
Number of subjects: 82
Study: 31518254

Group type: EXPERIMENTAL
Intervention: Photo story in paper format
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Photo story in tablet format
Number of subjects: 126

Group type: COMPARATOR
Intervention: Traditional brochure in paper format
Number of subjects: 126

Group type: COMPARATOR
Intervention: Traditional brochure in tablet format
Number of subjects: 126
Study: 31518270

Group type: EXPERIMENTAL
Intervention: Social Support Aid (SSA) mobile app
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 48
Study: 31518280

Group type: EXPERIMENTAL
Intervention: BrainCheck Memory
Number of subjects: 583

Group type: COMPARATOR
Intervention: Physician diagnosis
Number of subjects: 583
Study: 31518281

Group type: EXPERIMENTAL
Intervention: Jawbone Up24 activity monitor and Apple iPad Mini with UP app
Number of subjects: 35
Study: 31518302

Group type: EXPERIMENTAL
Intervention: Empowering youth towards employment e-mentoring intervention (mentored group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (nonmentored)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Empowering youth towards employment e-mentoring intervention
Number of subjects: 28
Study: 31518304

Group type: EXPERIMENTAL
Intervention: iThermonitor device for continuous temperature monitoring over a 2-week period
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: iThermonitor device
Number of subjects: 25
Study: 31518315

Group type: EXPERIMENTAL
Intervention: Empowering Youth Towards Employment intervention (e-mentoring), 12 modules over 12 weeks, led by trained mentors with physical disabilities.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (not mentored).
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intervention group (mentored).
Number of subjects: 13
Study: 31518364

Group type: EXPERIMENTAL
Intervention: MILD COPD
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: MILD EMPHYSEMATOUS
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: SEVERE BRONCHITIC
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: SEVERE EMPHYSEMATOUS
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: SEVERE MIXED COPD
Number of subjects: 514
Study: 31518417

Group type: EXPERIMENTAL
Intervention: CMR imaging-derived infarct characteristics
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: CMR-derived infarct characteristics
Number of subjects: 284
Study: 31518565

Group type: EXPERIMENTAL
Intervention: MoCA normal group (score of 25-30)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: MoCA mildly impaired group (score of 20-24)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: MoCA moderately impaired group (score less than 19)
Number of subjects: 334
Study: 31519154

Group type: EXPERIMENTAL
Intervention: Echocardiographic, biomarker, and clinical predictors
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Echocardiographic predictors and biomarkers
Number of subjects: 450
Study: 31519188

Group type: EXPERIMENTAL
Intervention: Identification of pathogens in nasopharyngeal aspirate (NPA) specimens for asthma exacerbation patients.
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Identification of pathogens in nasopharyngeal aspirate (NPA) specimens for AECOPD patients.
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Human rhinovirus (HRV) typing (HRV-A and HRV-C).
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Influenza A virus identification.
Number of subjects: 602